Ryman Healthcare Limited (RHCGF) Fair Value & Analysis
Healthcare · US · Market cap $3.2B
Ryman Healthcare Limited
RHCGF · US
Fair value as of: Jul 19, 2026
From 10 valuation models · updated today
Share price −23.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.08 – $1.75 · fair‑value band $0.1105 – $0.3740 · the $1.08 price screens above the $0.3740 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ryman Healthcare Limited (RHCGF) currently trades at $1.08, while our model-based Fair Value estimate is $0.3740, implying the stock looks roughly 65.4% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Ryman Healthcare Limited generated revenue of $854M at a net margin of -20.1%. Revenue grew 11.9% year over year. It earns a return on equity of -4.2%. Net debt stands at $1.6B. Fundamentals as of Jul 19, 2026
Our scenario range runs from $0.1105 (bear case) to $0.3740 (bull case); at $1.08, the current price sits above that range. The share trades about 38% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -65%, RHCGF screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia. The company's villages provide apartments and townhouses, and assisted-living in serviced apartments, and care center, which offers rest homes, hospitals, specialist dementia care, and respite care services. Ryman Healthcare Limited was founded in 1984 and is based in Christchurch, New Zealand.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Ryman Healthcare Limited reported revenue of $806M in FY2026 versus $504M in FY2022, a compound +12.5%/yr. Reported net income was −$173M in FY2026.
Is RHCGF fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FRE | €37.69 | €30.03 | -20% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
| DaVita Inc DVAI34 | R$1,170 | R$210.54 | -82% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,469 | ₹2,967 | -65% |
| Fresenius Medical Care AG FME | €41.25 | €80.11 | +94% |
| Aier Eye Hospital Group 300015 | ¥8.49 | ¥10.83 | +28% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,095 | ₹293.73 | -73% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ryman Healthcare Limited (RHCGF) undervalued?
What is the fair value of RHCGF?
What is the quality score of RHCGF?
What is the revenue of Ryman Healthcare Limited (RHCGF)?
What is the net profit margin of RHCGF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Ryman Healthcare Limited reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Ryman Healthcare Limited materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.